CSPC Group announced that the company previously disclosed that it signed a strategic research and development cooperation agreement with AstraZeneca on June 13, 2025 to discover and develop novel oral small molecule drug candidates. The company received a milestone payment of $10 million from AstraZeneca on August 5, 2026 to exercise the licensing option for one of the PCC projects under the terms of the agreement, indicating that related R&D work under the agreement is progressing steadily according to plan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.